Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BSPG CBD in Healthy Volunteers
NCT05269706Phase 1Completed
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cannabidiol in opioid use disorder (OUD) (2 arms). Primary endpoints: Systematic Assessment for Treatment Emergent Events at 24 hours, Peak Plasma Concentration at 24 hours and 1 more. Started May 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05269706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269706.